

해외 바이오의약품 임상 현황 (2020.01.07~2020.01.13)

한국바이오의약품협회, 2020.1.14.
출처: ClinicalTrials.gov

○ 미국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03971799	Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia	Acute Myelogenous Leukemia	Biological: CD33CART	Center for International Blood and Marrow Transplant Research National Marrow Donor Program St. Baldrick's Foundation	Phase 1 Phase 2
NCT04227106	Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)	Epidermolysis Bullosa Recessive Dystrophic Epidermolysis Bullosa	Biological: EB-101	Abeona Therapeutics, Inc	Phase 3
NCT04099836	Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib	Non Small Cell Lung Cancer	Drug: Atezolizumab Drug: Bevacizumab	Duke University	Phase 2
NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	Acute Biphenotypic Leukemia Acute Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Hairy Cell Leukemia Interleukin-3 Receptor Subunit Alpha Positive Recurrent Acute Lymphoblastic Leukemia Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Hematologic Malignancy Recurrent Hodgkin Lymphoma Refractory Acute Lymphoblastic Leukemia Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory Hematologic Malignancy Refractory Hodgkin Lymphoma Systemic Mastocytosis	Biological: Anti-CD123/CD3 Monoclonal Antibody MGD006	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2
NCT04186871	Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis	Autoimmune Disorder Rheumatoid Arthritis Systemic Lupus Erythematosus Primary Sjögren's Syndrome	Drug: branebrutinib Drug: abatacept Drug: branebrutinib placebo	Bristol-Myers Squibb	Phase 2
NCT04004611	A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)	Ulcerative Colitis	Drug: Mirikizumab	Eli Lilly and Company	Phase 2

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04186871	Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis	Autoimmune Disorder Rheumatoid Arthritis Systemic Lupus Erythematosus Primary Sjögren's Syndrome	Drug: branebrutinib Drug: abatacept Drug: branebrutinib placebo	Bristol-Myers Squibb	Phase 2

○ 프랑스 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04186871	Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis	Autoimmune Disorder Rheumatoid Arthritis Systemic Lupus Erythematosus Primary Sjögren's Syndrome	Drug: branebrutinib Drug: abatacept Drug: branebrutinib placebo	Bristol-Myers Squibb	Phase 2

○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04186871	Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis	Autoimmune Disorder Rheumatoid Arthritis Systemic Lupus Erythematosus Primary Sjögren's Syndrome	Drug: branebrutinib Drug: abatacept Drug: branebrutinib placebo	Bristol-Myers Squibb	Phase 2
NCT04204408	A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People and Patients With Bleeding Disorder	Healthy Volunteers Haemophilia A With or Without Inhibitors	Drug: NNC0365-3769 A (Mim8) Drug: Placebo (Mim8)	Novo Nordisk A/S	Phase 2

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04176016	Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma	Relapsed or Refractory Synovial Sarcoma	Drug: OTSA101-DTPA-111In Drug: OTSA101-DTPA-90Y	OncoTherapy Science, Inc.	Phase 1